COVID-19-vaccines

Allergic-reactions: 63 case reports

In a study involving 208 patients conducted from March 2021 to February 2022 in Italy, 63 patients including 7 men and 56 women (aged 22-78 years) were described, who developed urticaria, itching erythema, angioedema, asthma or oculorinitis following administration of Ad26.COV2-S, AZD-1222, elasomeran, tozinameran or influenza-virus-vaccine-quadrivalent-Novavax for COVID-19 vaccination [routes, dosages and exact time to reaction onsets not stated].

All the patients received COVID-19 vaccination. For COVID-19 vaccination, the patients received first dose of tozinameran [Cominarty; n=43], elasomeran [Spikevax; n=12], Ad26.COV2-S [manufactured by Janssen; n=2]; AZD-1222 [Vaxzveria; n=6]. For second dose, patient received tozinameran (n=52), influenza-virus-vaccine-quadrivalent-Novavax [manufactured by Novavax; n=1], elasomeran (n=8) or AZD-1222 (n=2). Only 19 patients amongst the 63 patients received third dose; for third dose, the patients received tozinameran (n=11) or elasomeran (n=8). However, all the patients developed allergic reactions at first dose (n=29), at both first and second doses (n=17), at second dose (n=11), at second and third doses (n=2), at third dose (n=3) or at first and third doses (n=1). The allergic reactions attributed to COVID-19 vaccination included urticaria (n=32); urticaria and asthma (n=1); itching and erythema (n=1); angioedema (n=7); erythema (n=10); itching (n=4); asthma (n=5) or oculorinitis (n=3).

For treatment of allergic reactions, patients received cortisone and unspecified antihistamine (n=11); unspecified antihistamine (n=15) or cortisone (n=10) [reaction outcomes not stated].

Filon FL, et al. Allergic Reactions to COVID-19 Vaccination in High-Risk Allergic Patients: The Experience of Trieste University Hospital (North-Eastern Italy). Vaccines 10: 1616, No. 10, Oct 2022. Available from: URL: http://www.mdpi.com/journal/vaccines